Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
866 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06492122 | Study With [225Ac]Ac-FL-020 in mCRPC Participants(ProTACT) | recruiting | Phase 1 | 50 | Full-Life Technologies UK LimitedINDUSTRY | 4 | May 26, 2026 | clinicaltrials |
| NCT06682988 | A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine | recruiting | Phase 2 | 110 | AbbVieINDUSTRY |
| 8 |
| May 26, 2026 |
| clinicaltrials |
| NCT03151629 | International Registry for Men With Advanced Prostate Cancer (IRONMAN)(IRONMAN) | recruiting | — | 5,000 | Prostate Cancer Clinical Trials ConsortiumOTHER | 15 | May 22, 2026 | clinicaltrials |
| NCT05277168 | A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS | recruiting | Phase 1 / Phase 2 | 83 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 4 | May 22, 2026 | clinicaltrials |
| NCT06656390 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 202 | Shanghai Allink Biotherapeutics Co., Ltd.INDUSTRY | 3 | May 22, 2026 | clinicaltrials |
| NCT06953089 | DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors | recruiting | Phase 2 | 450 | DualityBio Inc.INDUSTRY | 4 | May 22, 2026 | clinicaltrials |
| NCT07263594 | A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors | recruiting | Phase 1 / Phase 2 | 127 | DualityBio Inc.INDUSTRY | 3 | May 22, 2026 | clinicaltrials |
| NCT04086082 | Markerless Image Guidance Using Intrafraction Kilovoltage X-ray Imaging(MAGIK) | recruiting | N/A | 30 | University of SydneyOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06494254 | Post-Operative Prediction of PulmonarY Function(POPPY) | recruiting | — | 15 | University of SydneyOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT07334119 | Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors | recruiting | Phase 1 | 60 | Myeloid TherapeuticsINDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT05030207 | Respiratory Adaptive Computed Tomography: Feasibility Study on Real-Time Gated 4DCT for Lung Cancer Radiotherapy(REACT) | recruiting | N/A | 30 | University of SydneyOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT05169177 | Radio-opaque Contrast Agents for Liver Cancer Targeting With KIM During Radiation Therapy(ROCK-RT) | recruiting | — | 50 | University of SydneyOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT05184790 | LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology(LEARN) | recruiting | — | 300 | University of SydneyOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT05500612 | MRI Hypoxia Study for Glioblastoma Multiforme (GBM) Radiation Therapy(MANGO) | recruiting | — | 20 | University of SydneyOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT06127654 | Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation Therapy(VITaL) | recruiting | Phase 3 | 165 | University of SydneyOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT06159660 | Ventilation Using Radiographic Examination: Functional Lung Imaging Techniques for the Reduction of Toxicity in Functional Avoidance Radiation Therapy(VENTURE) | recruiting | — | 15 | University of SydneyOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT06588478 | A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | recruiting | Phase 2 | 249 | Loxo Oncology, Inc.INDUSTRY | 18 | May 19, 2026 | clinicaltrials |
| NCT01790152 | Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment | recruiting | — | 420 | Children's Oncology GroupNETWORK | 4 | May 18, 2026 | clinicaltrials |
| NCT06400485 | AMT-676 in Patients With Advanced Solid Tumors | recruiting | Early Phase 1 | 24 | Multitude Therapeutics Inc.INDUSTRY | 3 | May 18, 2026 | clinicaltrials |
| NCT06757634 | Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | recruiting | Phase 3 | 1,180 | Celcuity IncINDUSTRY | 22 | May 18, 2026 | clinicaltrials |
| NCT01696721 | Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy | recruiting | — | 5,000 | Massachusetts General HospitalOTHER | 3 | May 14, 2026 | clinicaltrials |
| NCT06284317 | A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.(ADOPT-lung) | recruiting | Phase 3 | 290 | ETOP IBCSG Partners FoundationNETWORK | 10 | May 14, 2026 | clinicaltrials |
| NCT06417814 | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(TROPION-Lung15) | recruiting | Phase 3 | 744 | AstraZenecaINDUSTRY | 27 | May 14, 2026 | clinicaltrials |
| NCT06879041 | A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 136 | AstraZenecaINDUSTRY | 3 | May 12, 2026 | clinicaltrials |
| NCT00843375 | Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas | recruiting | — | 1,200 | University of Michigan Rogel Cancer CenterOTHER | 3 | May 11, 2026 | clinicaltrials |
| NCT06290505 | A Trial of Palliative Chemotherapy, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study(PALEO) | recruiting | Phase 2 | 54 | Australasian Gastro-Intestinal Trials GroupNETWORK | 2 | May 8, 2026 | clinicaltrials |
| NCT06604533 | Magnetic Resonance Imaging (MRI) Guided Stereotactic Adaptive Radiotherapy for Targeting Abdominal Cancer | recruiting | N/A | 30 | Australasian Gastro-Intestinal Trials GroupNETWORK | 1 | May 8, 2026 | clinicaltrials |
| NCT06697301 | Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. | recruiting | Phase 2 / Phase 3 | 740 | Eikon TherapeuticsINDUSTRY | 24 | May 8, 2026 | clinicaltrials |
| NCT06767306 | Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma(AXIOM) | recruiting | Phase 2 | 129 | Melanoma Institute AustraliaOTHER | 2 | May 7, 2026 | clinicaltrials |
| NCT06023862 | A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)(DOVE) | recruiting | Phase 2 | 198 | Yonsei UniversityOTHER | 7 | May 6, 2026 | clinicaltrials |
| NCT06441747 | Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) | recruiting | Phase 2 | 40 | Australasian Gastro-Intestinal Trials GroupNETWORK | 1 | May 6, 2026 | clinicaltrials |
| NCT06819735 | Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors(DOMISOL) | recruiting | Phase 1 / Phase 2 | 125 | Domain Therapeutics Australia Pty LtdINDUSTRY | 3 | May 6, 2026 | clinicaltrials |
| NCT06898450 | A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. | recruiting | Phase 1 / Phase 2 | 134 | Nimbus Wadjet, Inc.INDUSTRY | 8 | May 6, 2026 | clinicaltrials |
| NCT07015190 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | recruiting | Phase 3 | 520 | IDEAYA BiosciencesINDUSTRY | 21 | May 6, 2026 | clinicaltrials |
| NCT05983159 | A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations(TARGET-VM) | recruiting | Phase 2 | 50 | Murdoch Childrens Research InstituteOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07399977 | Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism | recruiting | N/A | 259 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | May 5, 2026 | clinicaltrials |
| NCT05458219 | A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors | recruiting | Phase 1 | 470 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 3 | May 4, 2026 | clinicaltrials |
| NCT07249905 | Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma | recruiting | Phase 1 / Phase 2 | 180 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT07300943 | Study in Advanced Solid Tumor Patients | recruiting | Phase 1 / Phase 2 | 306 | Callio TherapeuticsINDUSTRY | 2 | May 1, 2026 | clinicaltrials |
| NCT06051409 | A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) | recruiting | Phase 3 | 350 | Ascentage Pharma Group Inc.INDUSTRY | 12 | Apr 30, 2026 | clinicaltrials |
| NCT07552922 | Determining INdividual Preferences for Gynecomastia avOidance (DINGO) - Stage 1(DINGO) | recruiting | N/A | 24 | St Vincent's Hospital, SydneyOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT06594926 | Working Out M0 Bipolar Androgen Therapy(WOMBAT) | recruiting | Phase 2 | 69 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06816992 | ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC | recruiting | Phase 1 | 76 | ORIC PharmaceuticalsINDUSTRY | 3 | Apr 24, 2026 | clinicaltrials |
| NCT03522064 | Bipolar Androgen Therapy + Carboplatin in mCRPC(HiTeCH) | recruiting | Phase 2 | 30 | St Vincent's Hospital, SydneyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05233397 | ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | recruiting | Phase 2 | 30 | Nationwide Children's HospitalOTHER | 3 | Apr 23, 2026 | clinicaltrials |
| NCT05465174 | Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults(PNOC029) | recruiting | Phase 2 | 57 | Sabine Mueller, MD, PhDOTHER | 2 | Apr 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials